annotation_id large_string | subject large_string | rsid large_string | gene large_string | genotype large_string | evidence_level large_string | phenotype_category large_string | drugs large_string | phenotypes large_string | annotation_text large_string | url large_string |
|---|---|---|---|---|---|---|---|---|---|---|
1043880467 | rs4986790 | rs4986790 | TLR4 | AG | 3 | Toxicity | folic acid;methotrexate | Rheumatoid arthritis | Patients with the AG genotype and Rheumatoid Arthritis who are treated with folic acid and methotrexate may have a decreased risk of adverse drug events as compared to patients with the GG genotype, or may have an increased risk of adverse drug events as compared to patients with the AA genotype. Other genetic and clin... | https://www.clinpgx.org/clinicalAnnotation/1043880467 |
1043880467 | rs4986790 | rs4986790 | TLR4 | GG | 3 | Toxicity | folic acid;methotrexate | Rheumatoid arthritis | Patients with the GG genotype and Rheumatoid Arthritis who are treated with folic acid and methotrexate may have an increased risk of adverse drug events as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to folic acid and methotrexate treatment. | https://www.clinpgx.org/clinicalAnnotation/1043880467 |
1043880476 | rs5186 | rs5186 | AGTR1 | AA | 3 | Efficacy;Toxicity | Ace Inhibitors, Plain | Coronary Artery Disease | Patients with the AA genotype and Coronary Artery Disease may have a decreased major cardiovascular events rate when treated with Ace Inhibitors as compared to patients with the CC and CA genotype. Other genetic and clinical factors may also influence a patient's risk for major cardiovascular events. | https://www.clinpgx.org/clinicalAnnotation/1043880476 |
1043880476 | rs5186 | rs5186 | AGTR1 | CA | 3 | Efficacy;Toxicity | Ace Inhibitors, Plain | Coronary Artery Disease | Patients with the CA genotype and Coronary Artery Disease may have an increased major cardiovascular events rate when treated with Ace Inhibitors as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk for major cardiovascular events. | https://www.clinpgx.org/clinicalAnnotation/1043880476 |
1043880476 | rs5186 | rs5186 | AGTR1 | CC | 3 | Efficacy;Toxicity | Ace Inhibitors, Plain | Coronary Artery Disease | Patients with the CC genotype and Coronary Artery Disease may have an increased major cardiovascular events rate when treated with Ace Inhibitors as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk for major cardiovascular events. | https://www.clinpgx.org/clinicalAnnotation/1043880476 |
1043880520 | SLCO1B1*1, SLCO1B1*5, SLCO1B1*15 | null | SLCO1B1 | *1 | 1A | Metabolism/PK | pravastatin | null | The SLCO1B1*1 allele is assigned as a normal function allele by CPIC. Patients with the *1 allele in combination with another normal function allele may have decreased bioavailability of pravastatin as compared to individuals with with a no function allele in combination with a normal or increased function allele or wi... | https://www.clinpgx.org/clinicalAnnotation/1043880520 |
1043880520 | SLCO1B1*1, SLCO1B1*5, SLCO1B1*15 | null | SLCO1B1 | *15 | 1A | Metabolism/PK | pravastatin | null | The SLCO1B1*15 allele (defined as consisting of both rs4149056 and rs2306283) is assigned as a no function allele by CPIC. Patients with the *15 allele in combination with a normal, no, or increased function allele may have increased bioavailability of pravastatin as compared to individuals with two normal function all... | https://www.clinpgx.org/clinicalAnnotation/1043880520 |
1043880520 | SLCO1B1*1, SLCO1B1*5, SLCO1B1*15 | null | SLCO1B1 | *5 | 1A | Metabolism/PK | pravastatin | null | The SLCO1B1*5 allele (defined as consisting of rs4149056) is assigned as a no function allele by CPIC. Patients with the *5 allele in combination with a normal, no, or increased function allele may have increased bioavailability of pravastatin as compared to individuals with two normal function alleles. Other genetic a... | https://www.clinpgx.org/clinicalAnnotation/1043880520 |
1043880567 | rs2306283 | rs2306283 | SLCO1B1 | AA | 3 | Other | pitavastatin | null | Patients with the AA genotype may have decreased pitavastatin plasma concentrations as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence a patient's pitavastatin pharmacokinetics. | https://www.clinpgx.org/clinicalAnnotation/1043880567 |
1043880567 | rs2306283 | rs2306283 | SLCO1B1 | AG | 3 | Other | pitavastatin | null | Patients with the AG genotype may have increased pitavastatin plasma concentrations as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's pitavastatin pharmacokinetics. | https://www.clinpgx.org/clinicalAnnotation/1043880567 |
1043880567 | rs2306283 | rs2306283 | SLCO1B1 | GG | 3 | Other | pitavastatin | null | Patients with the GG genotype may have increased pitavastatin plasma concentrations as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's pitavastatin pharmacokinetics. | https://www.clinpgx.org/clinicalAnnotation/1043880567 |
1043880608 | rs2306283 | rs2306283 | SLCO1B1 | AA | 4 | Efficacy | atorvastatin | Hypercholesterolemia | The current evidence base suggests that there is no significant association between the rs2306283 AA genotype and response to atorvastatin. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to atorvastatin. | https://www.clinpgx.org/clinicalAnnotation/1043880608 |
1043880608 | rs2306283 | rs2306283 | SLCO1B1 | AG | 4 | Efficacy | atorvastatin | Hypercholesterolemia | The current evidence base suggests that there is no significant association between the rs2306283 AG genotype and response to atorvastatin. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to atorvastatin. | https://www.clinpgx.org/clinicalAnnotation/1043880608 |
1043880608 | rs2306283 | rs2306283 | SLCO1B1 | GG | 4 | Efficacy | atorvastatin | Hypercholesterolemia | The current evidence base suggests that there is no significant association between the rs2306283 GG genotype and response to atorvastatin. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to atorvastatin. | https://www.clinpgx.org/clinicalAnnotation/1043880608 |
1043880630 | SLCO1B1*1, SLCO1B1*5, SLCO1B1*15, SLCO1B1*37 | null | SLCO1B1 | *1 | 1A | Metabolism/PK | atorvastatin | null | The SLCO1B1*1 allele is assigned as a normal function allele by CPIC. Patients with the SLCO1B1*1 allele in combination with another normal function allele may have decreased atorvastatin concentrations as compared to patients with a no function allele in combination with a normal or increased function allele or with t... | https://www.clinpgx.org/clinicalAnnotation/1043880630 |
1043880630 | SLCO1B1*1, SLCO1B1*5, SLCO1B1*15, SLCO1B1*37 | null | SLCO1B1 | *15 | 1A | Metabolism/PK | atorvastatin | null | The SLCO1B1*15 allele (defined as consisting of both rs4149056 and rs2306283) is assigned as a no function allele by CPIC. Patients carrying SLCO1B1*15 allele in combination with a normal, no, or increased function allele may have increased atorvastatin concentrations as compared to patients with two normal function al... | https://www.clinpgx.org/clinicalAnnotation/1043880630 |
1043880630 | SLCO1B1*1, SLCO1B1*5, SLCO1B1*15, SLCO1B1*37 | null | SLCO1B1 | *37 | 1A | Metabolism/PK | atorvastatin | null | The SLCO1B1*37 allele (defined as consisting of rs2306283) is assigned as a normal function allele by CPIC. Patients with the SLCO1B1*37 allele in combination with another normal function allele may have decreased atorvastatin concentrations as compared to patients with a no function allele in combination with a normal... | https://www.clinpgx.org/clinicalAnnotation/1043880630 |
1043880630 | SLCO1B1*1, SLCO1B1*5, SLCO1B1*15, SLCO1B1*37 | null | SLCO1B1 | *5 | 1A | Metabolism/PK | atorvastatin | null | The SLCO1B1*5 allele (defined as consisting of rs4149056) is assigned as a no function allele by CPIC. Patients carrying SLCO1B1*5 allele in combination with a normal, no, or increased function allele may have increased atorvastatin concentrations as compared to patients with two normal function alleles. This annotatio... | https://www.clinpgx.org/clinicalAnnotation/1043880630 |
1043880644 | rs495828 | rs495828 | ABO | GG | 3 | Toxicity | Ace Inhibitors, Plain | null | Patients with the GG genotype may have a decreased, but not absent, risk for angiotensin-converting enzyme inhibitors-induced cough when treated with Ace Inhibitors as compared to patients with the TT or TG genotype. Other genetic and clinical factors may also influence a patient's risk for angiotensin-converting enzym... | https://www.clinpgx.org/clinicalAnnotation/1043880644 |
1043880644 | rs495828 | rs495828 | ABO | TG | 3 | Toxicity | Ace Inhibitors, Plain | null | Patients with the TG genotype may have an increased risk for angiotensin-converting enzyme inhibitors-induced cough when treated with Ace Inhibitors as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk for angiotensin-converting enzyme inhibitors-induced c... | https://www.clinpgx.org/clinicalAnnotation/1043880644 |
1043880644 | rs495828 | rs495828 | ABO | TT | 3 | Toxicity | Ace Inhibitors, Plain | null | Patients with the TT genotype may have an increased risk for angiotensin-converting enzyme inhibitors-induced cough when treated with Ace Inhibitors as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk for angiotensin-converting enzyme inhibitors-induced c... | https://www.clinpgx.org/clinicalAnnotation/1043880644 |
1043880649 | rs4459610 | rs4459610 | null | AA | 3 | Toxicity | Ace Inhibitors, Plain | Cough | Patients with the AA genotype who are treated with ACE inhibitors may have a decreased, but not absent, risk for cough as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk for cough. | https://www.clinpgx.org/clinicalAnnotation/1043880649 |
1043880649 | rs4459610 | rs4459610 | null | AT | 3 | Toxicity | Ace Inhibitors, Plain | Cough | Patients with the AT genotype who are treated with ACE inhibitors may have a decreased, but not absent, risk for cough as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk for cough. | https://www.clinpgx.org/clinicalAnnotation/1043880649 |
1043880649 | rs4459610 | rs4459610 | null | TT | 3 | Toxicity | Ace Inhibitors, Plain | Cough | Patients with the TT genotype who are treated with ACE inhibitors may have an increased risk for cough as compared to patients with the AT or AA genotype. Other genetic and clinical factors may also influence a patient's risk for cough. | https://www.clinpgx.org/clinicalAnnotation/1043880649 |
1043880654 | rs4267385 | rs4267385 | null | CC | 3 | Toxicity | Ace Inhibitors, Plain | Cough | Patients with the CC genotype and homozygous carrier for the GG genotype for rs4343 who are treated with ACE inhibitors may have a decreased, but not absent, risk for cough as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk for cough. | https://www.clinpgx.org/clinicalAnnotation/1043880654 |
1043880654 | rs4267385 | rs4267385 | null | CT | 3 | Toxicity | Ace Inhibitors, Plain | Cough | Patients with the CT genotype and homozygous carrier for the GG genotype for rs4343 who are treated with ACE inhibitors may have a decreased, but not absent, risk for cough as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk for cough. | https://www.clinpgx.org/clinicalAnnotation/1043880654 |
1043880654 | rs4267385 | rs4267385 | null | TT | 3 | Toxicity | Ace Inhibitors, Plain | Cough | Patients with the TT genotype and homozygous carrier for the GG genotype for rs4343 who are treated with ACE inhibitors may have an increased risk for cough as compared to patients with the CT or CC genotype. Other genetic and clinical factors may also influence a patient's risk for cough. | https://www.clinpgx.org/clinicalAnnotation/1043880654 |
1043880659 | rs2207396 | rs2207396 | ESR1 | AA | 3 | Toxicity | Alkylating Agents;cisplatin | Neoplasms | Patients with the AA genotype and childhood cancer who are treated with Alkylating Agents and cisplatin may have an increased risk of azoospermia as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to Alkylating Agents and cisplatin treatment. | https://www.clinpgx.org/clinicalAnnotation/1043880659 |
1043880659 | rs2207396 | rs2207396 | ESR1 | AG | 3 | Toxicity | Alkylating Agents;cisplatin | Neoplasms | Patients with the AG genotype and childhood cancer who are treated with Alkylating Agents and cisplatin may have an increased risk of azoospermia as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to Alkylating Agents and cisplatin treatment. | https://www.clinpgx.org/clinicalAnnotation/1043880659 |
1043880659 | rs2207396 | rs2207396 | ESR1 | GG | 3 | Toxicity | Alkylating Agents;cisplatin | Neoplasms | Patients with the GG genotype and childhood cancer who are treated with Alkylating Agents and cisplatin may have a decreased, but not absent, risk of azoospermia as compared to patients with the AG or AA genotype. Other genetic and clinical factors may also influence a patient's response to Alkylating Agents and cispla... | https://www.clinpgx.org/clinicalAnnotation/1043880659 |
1043880664 | rs510769 | rs510769 | OPRM1 | CC | 3 | Efficacy | amphetamine | null | Patients with the CC genotype may have increased Stimulation and Euphoria scores after amphetamine exposure as compared to patients with the TT genotype. | https://www.clinpgx.org/clinicalAnnotation/1043880664 |
1043880664 | rs510769 | rs510769 | OPRM1 | CT | 3 | Efficacy | amphetamine | null | Patients with the CT genotype may have increased Stimulation and Euphoria scores after amphetamine exposure as compared to patients with the TT genotype. | https://www.clinpgx.org/clinicalAnnotation/1043880664 |
1043880664 | rs510769 | rs510769 | OPRM1 | TT | 3 | Efficacy | amphetamine | null | Patients with the TT genotype may have decreased Stimulation and Euphoria scores after amphetamine exposure as compared to patients with the CC or CT genotype. | https://www.clinpgx.org/clinicalAnnotation/1043880664 |
1043880669 | rs2281617 | rs2281617 | OPRM1 | CC | 3 | Other | amphetamine | null | Patients with the CC genotype may have increased Euphoric and Energetic after amphetamine exposure as compared to patients with the CT or TT genotype. | https://www.clinpgx.org/clinicalAnnotation/1043880669 |
1043880669 | rs2281617 | rs2281617 | OPRM1 | CT | 3 | Other | amphetamine | null | Patients with the CT genotype may have decreased Euphoric and Energetic after amphetamine exposure as compared to patients with the CC genotype. | https://www.clinpgx.org/clinicalAnnotation/1043880669 |
1043880669 | rs2281617 | rs2281617 | OPRM1 | TT | 3 | Other | amphetamine | null | Patients with the TT genotype may have decreased Euphoric and Energetic after amphetamine exposure as compared to patients with the CC genotype. | https://www.clinpgx.org/clinicalAnnotation/1043880669 |
1043880680 | rs5030655 | rs5030655 | CYP2D6 | AA | 3 | Toxicity | antipsychotics | null | Patients with the AA genotype who are treated with antipsychotics may have a decreased, but not absent, risk for antipsychotic-induced extrapyramidal symptoms as compared to patients with the DEL/A or DEL/DEL genotype. Other genetic and clinical factors may also influence a patient's response to treatment with antipsyc... | https://www.clinpgx.org/clinicalAnnotation/1043880680 |
1043880680 | rs5030655 | rs5030655 | CYP2D6 | DEL/A | 3 | Toxicity | antipsychotics | null | Patients with the DEL/A genotype who are treated with antipsychotics may have an increased risk for antipsychotic-induced extrapyramidal symptoms as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to treatment with antipsychotics. | https://www.clinpgx.org/clinicalAnnotation/1043880680 |
1043880680 | rs5030655 | rs5030655 | CYP2D6 | DEL/DEL | 3 | Toxicity | antipsychotics | null | Patients with the DEL/DEL genotype who are treated with antipsychotics may have an increased risk for antipsychotic-induced extrapyramidal symptoms as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to treatment with antipsychotics. | https://www.clinpgx.org/clinicalAnnotation/1043880680 |
1043880701 | SLCO1B1*1, SLCO1B1*5, SLCO1B1*9, SLCO1B1*14, SLCO1B1*15, SLCO1B1*37 | null | SLCO1B1 | *1 | 1A | Metabolism/PK | rosuvastatin | null | The SLCO1B1*1 allele is assigned as a normal function allele by CPIC. Patients with the *1 allele in combination with another normal function allele may have decreased exposure to rosuvastatin as compared to patients with a no function allele in combination with a normal or increased function allele or with two no func... | https://www.clinpgx.org/clinicalAnnotation/1043880701 |
1043880701 | SLCO1B1*1, SLCO1B1*5, SLCO1B1*9, SLCO1B1*14, SLCO1B1*15, SLCO1B1*37 | null | SLCO1B1 | *14 | 1A | Metabolism/PK | rosuvastatin | null | The SLCO1B1*14 allele (defined as consisting of rs2306283 and rs11045819) is assigned as an increased function allele by CPIC. Patients with the *14 allele in combination with another increased or normal function allele may have decreased exposure to rosuvastatin as compared to patients with a no function allele in com... | https://www.clinpgx.org/clinicalAnnotation/1043880701 |
1043880701 | SLCO1B1*1, SLCO1B1*5, SLCO1B1*9, SLCO1B1*14, SLCO1B1*15, SLCO1B1*37 | null | SLCO1B1 | *15 | 1A | Metabolism/PK | rosuvastatin | null | The SLCO1B1*15 allele (defined as consisting of both rs4149056 and rs2306283) is assigned as a no function allele by CPIC. Patients with the *15 allele in combination of a normal, no, or increased function allele may have increased exposure to rosuvastatin as compared to patients with two normal function alleles. Other... | https://www.clinpgx.org/clinicalAnnotation/1043880701 |
1043880701 | SLCO1B1*1, SLCO1B1*5, SLCO1B1*9, SLCO1B1*14, SLCO1B1*15, SLCO1B1*37 | null | SLCO1B1 | *37 | 1A | Metabolism/PK | rosuvastatin | null | The SLCO1B1*37 allele (defined as consisting of rs2306283) is assigned as a normal function allele by CPIC. Patients with the *37 allele in combination with another normal function allele may have decreased exposure to rosuvastatin as compared to patients with a no function allele in combination with a normal or increa... | https://www.clinpgx.org/clinicalAnnotation/1043880701 |
1043880701 | SLCO1B1*1, SLCO1B1*5, SLCO1B1*9, SLCO1B1*14, SLCO1B1*15, SLCO1B1*37 | null | SLCO1B1 | *5 | 1A | Metabolism/PK | rosuvastatin | null | The SLCO1B1*5 allele (defined as consisting of rs4149056) is assigned as a no function allele by CPIC. Patients with the *5 allele in combination with a normal, no, or increased function allele may have increased exposure to rosuvastatin as compared to patients with two normal function alleles. Other genetic and clinic... | https://www.clinpgx.org/clinicalAnnotation/1043880701 |
1043880701 | SLCO1B1*1, SLCO1B1*5, SLCO1B1*9, SLCO1B1*14, SLCO1B1*15, SLCO1B1*37 | null | SLCO1B1 | *9 | 1A | Metabolism/PK | rosuvastatin | null | The SLCO1B1*9 allele (defined as consisting of rs59502379) is assigned as a no function allele by CPIC. Patients with *9 allele in combination with a normal, no, or increased function allele may have increased exposure to rosuvastatin as compared to patients with two normal function alleles. Other genetic and clinical ... | https://www.clinpgx.org/clinicalAnnotation/1043880701 |
1043880723 | rs4606 | rs4606 | RGS2 | CC | 3 | Toxicity | antipsychotics | Schizophrenia | Patients with the CC genotype and Schizophrenia who are treated antipsychotics with may have an increased risk for antipsychotic-induced parkinsonism as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk for antipsychotic-induced parkinsonism. | https://www.clinpgx.org/clinicalAnnotation/1043880723 |
1043880723 | rs4606 | rs4606 | RGS2 | GC | 3 | Toxicity | antipsychotics | Schizophrenia | Patients with the GC genotype and Schizophrenia who are treated antipsychotics with may have a decreased, but not absent, risk for antipsychotic-induced parkinsonism as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk for antipsychotic-induced parkinsonis... | https://www.clinpgx.org/clinicalAnnotation/1043880723 |
1043880723 | rs4606 | rs4606 | RGS2 | GG | 3 | Toxicity | antipsychotics | Schizophrenia | Patients with the GG genotype and Schizophrenia who are treated antipsychotics with may have a decreased, but not absent, risk for antipsychotic-induced parkinsonism as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk for antipsychotic-induced parkinsonis... | https://www.clinpgx.org/clinicalAnnotation/1043880723 |
1043880750 | rs324420 | rs324420 | FAAH | AA | 3 | Toxicity | aripiprazole;clozapine;haloperidol;olanzapine;quetiapine;risperidone | Psychotic Disorder | Patients with the AA genotype and Psychotic Disorders who are treated with aripiprazole, clozapine, haloperidol, olanzapine, quetiapine or risperidone may have an increased likelihood of weight gain of more than 7% of baseline body weight as compared to patients with the CC genotype. However, this is contradicted in on... | https://www.clinpgx.org/clinicalAnnotation/1043880750 |
1043880750 | rs324420 | rs324420 | FAAH | AC | 3 | Toxicity | aripiprazole;clozapine;haloperidol;olanzapine;quetiapine;risperidone | Psychotic Disorder | Patients with the AC genotype and Psychotic Disorders who are treated with aripiprazole, clozapine, haloperidol, olanzapine, quetiapine or risperidone may have an increased likelihood of weight gain of more than 7% of baseline body weight as compared to patients with the CC genotype. However, this is contradicted in on... | https://www.clinpgx.org/clinicalAnnotation/1043880750 |
1043880750 | rs324420 | rs324420 | FAAH | CC | 3 | Toxicity | aripiprazole;clozapine;haloperidol;olanzapine;quetiapine;risperidone | Psychotic Disorder | Patients with the CC genotype and Psychotic Disorders who are treated with aripiprazole, clozapine, haloperidol, olanzapine, quetiapine or risperidone may have a decreased likelihood of weight gain of more than 7% of baseline body weight as compared to patients with the AA or AC genotype. However, this is contradicted ... | https://www.clinpgx.org/clinicalAnnotation/1043880750 |
1043880783 | rs11039149 | rs11039149 | NR1H3 | AA | 3 | Toxicity | atenolol;verapamil | Coronary Artery Disease;Hypertension | Patients with the AA genotype and hypertension and coronary artery disease who are treated with atenolol and verapamil may have a decreased, but not absent, risk for cardiovascular events as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk for cardiovascu... | https://www.clinpgx.org/clinicalAnnotation/1043880783 |
1043880783 | rs11039149 | rs11039149 | NR1H3 | GA | 3 | Toxicity | atenolol;verapamil | Coronary Artery Disease;Hypertension | Patients with the GA genotype and hypertension and coronary artery disease who are treated with atenolol and verapamil may have an increased risk for cardiovascular events as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk for cardiovascular events. | https://www.clinpgx.org/clinicalAnnotation/1043880783 |
1043880783 | rs11039149 | rs11039149 | NR1H3 | GG | 3 | Toxicity | atenolol;verapamil | Coronary Artery Disease;Hypertension | Patients with the GG genotype and hypertension and coronary artery disease who are treated with atenolol and verapamil may have an increased risk for cardiovascular events as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk for cardiovascular events. | https://www.clinpgx.org/clinicalAnnotation/1043880783 |
1043880792 | rs5443 | rs5443 | GNB3 | CC | 3 | Efficacy | atenolol | Essential hypertension | Patients with the CC genotype and essential hypertension who are treated with atenolol may have an increased response as compared to patients with the TT or CT genotype. However, contradictory findings are reported. Other genetic and clinical factors may also influence a patient's response to atenolol. | https://www.clinpgx.org/clinicalAnnotation/1043880792 |
1043880792 | rs5443 | rs5443 | GNB3 | CT | 3 | Efficacy | atenolol | Essential hypertension | Patients with the CT genotype and essential hypertension who are treated with atenolol may have a decreased response as compared to patients with the CC genotype. However, contradictory findings are reported. Other genetic and clinical factors may also influence a patient's response to atenolol. | https://www.clinpgx.org/clinicalAnnotation/1043880792 |
1043880792 | rs5443 | rs5443 | GNB3 | TT | 3 | Efficacy | atenolol | Essential hypertension | Patients with the TT genotype and essential hypertension who are treated with atenolol may have a decreased response as compared to patients with the CC genotype. However, contradictory findings are reported. Other genetic and clinical factors may also influence a patient's response to atenolol. | https://www.clinpgx.org/clinicalAnnotation/1043880792 |
1043880802 | rs4149056 | rs4149056 | SLCO1B1 | CC | 3 | Efficacy | pravastatin | null | Patients with the rs4149056 CC genotype who are treated with pravastatin may have a smaller reduction in LDL and total cholesterol as compared to patients with the TT genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence a patient's response to pravastatin trea... | https://www.clinpgx.org/clinicalAnnotation/1043880802 |
1043880802 | rs4149056 | rs4149056 | SLCO1B1 | CT | 3 | Efficacy | pravastatin | null | Patients with the rs4149056 CT genotype who are treated with pravastatin may have a smaller reduction in LDL and total cholesterol as compared to patients with the TT genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence a patient's response to pravastatin trea... | https://www.clinpgx.org/clinicalAnnotation/1043880802 |
1043880802 | rs4149056 | rs4149056 | SLCO1B1 | TT | 3 | Efficacy | pravastatin | null | Patients with the rs4149056 TT genotype who are treated with pravastatin may have a larger reduction in LDL and total cholesterol as compared to patients with the CC or CT genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence a patient's response to pravastatin... | https://www.clinpgx.org/clinicalAnnotation/1043880802 |
1043880812 | UGT1A3*1, UGT1A3*2 | null | UGT1A3 | *1/*1 | 3 | Efficacy | atorvastatin | null | Patients with the UGT1A3*1/*1 genotype may have a decreased atorvastatin lactonization as compared to patients with the UGT1A3*2/*2 genotype. Other genetic and clinical factors may also influence a patient's atorvastatin metabolism. | https://www.clinpgx.org/clinicalAnnotation/1043880812 |
1043880812 | UGT1A3*1, UGT1A3*2 | null | UGT1A3 | *2/*2 | 3 | Efficacy | atorvastatin | null | Patients with the UGT1A3*2/*2 genotype may have an increased atorvastatin lactonization as compared to patients with the UGT1A3*1/*1 genotype. Other genetic and clinical factors may also influence a patient's atorvastatin metabolism. | https://www.clinpgx.org/clinicalAnnotation/1043880812 |
1043880818 | rs4149056 | rs4149056 | SLCO1B1 | CC | 1A | Toxicity | atorvastatin | statin-related myopathy | Patients with the rs4149056 CC genotype may have an increased risk of myopathy when treated with atorvastatin as compared to patients with the TT genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of developing myopathy when treated with atorvastatin. | https://www.clinpgx.org/clinicalAnnotation/1043880818 |
1043880818 | rs4149056 | rs4149056 | SLCO1B1 | CT | 1A | Toxicity | atorvastatin | statin-related myopathy | Patients with the rs4149056 CT genotype may have an increased risk of myopathy when treated with atorvastatin as compared to patients with the TT genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of developing myopathy when treated with atorvastatin. | https://www.clinpgx.org/clinicalAnnotation/1043880818 |
1043880818 | rs4149056 | rs4149056 | SLCO1B1 | TT | 1A | Toxicity | atorvastatin | statin-related myopathy | Patients with the rs4149056 TT genotype may have a decreased risk of myopathy when treated with atorvastatin as compared to patients with the CC or CT genotypes. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of developing myopathy when treated with atorvasta... | https://www.clinpgx.org/clinicalAnnotation/1043880818 |
1043880823 | rs3808607 | rs3808607 | CYP7A1 | GG | 3 | Efficacy | atorvastatin | null | Patients with the GG genotype may have a decreased response to atorvastatin as compared to patients with the TT genotype. However, contradictory findings are reported. Other genetic and clinical factors may also influence a patient's response to atorvastatin. | https://www.clinpgx.org/clinicalAnnotation/1043880823 |
1043880823 | rs3808607 | rs3808607 | CYP7A1 | GT | 3 | Efficacy | atorvastatin | null | Patients with the GT genotype may have a decreased response to atorvastatin as compared to patients with the TT genotype. However, contradictory findings are reported. Other genetic and clinical factors may also influence a patient's response to atorvastatin. | https://www.clinpgx.org/clinicalAnnotation/1043880823 |
1043880823 | rs3808607 | rs3808607 | CYP7A1 | TT | 3 | Efficacy | atorvastatin | null | Patients with the TT genotype may have an increased response to atorvastatin as compared to patients with the GG or GT genotype. However, contradictory findings are reported. Other genetic and clinical factors may also influence a patient's response to atorvastatin. | https://www.clinpgx.org/clinicalAnnotation/1043880823 |
1043880828 | rs55754655 | rs55754655 | AOX1 | AA | 3 | Efficacy | azathioprine | Inflammatory Bowel Diseases | Patients with the AA genotype and Inflammatory Bowel Disease who are treated with azathioprine may have an increased response as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to azathioprine. | https://www.clinpgx.org/clinicalAnnotation/1043880828 |
1043880828 | rs55754655 | rs55754655 | AOX1 | GA | 3 | Efficacy | azathioprine | Inflammatory Bowel Diseases | Patients with the GA genotype and Inflammatory Bowel Disease who are treated with azathioprine may have a decreased response as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to azathioprine. | https://www.clinpgx.org/clinicalAnnotation/1043880828 |
1043880828 | rs55754655 | rs55754655 | AOX1 | GG | 3 | Efficacy | azathioprine | Inflammatory Bowel Diseases | Patients with the GG genotype and Inflammatory Bowel Disease who are treated with azathioprine may have a decreased response as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to azathioprine. | https://www.clinpgx.org/clinicalAnnotation/1043880828 |
1043880841 | rs1979277 | rs1979277 | SHMT1 | AA | 3 | Efficacy | bevacizumab;fluorouracil;irinotecan;leucovorin | Colorectal Neoplasms | Patients with the AA genotype and Colorectal Neoplasms may have 1) increased response, 2) increased progression-free survival and overall survival when treated with bevacizumab, fluorouracil, irinotecan and leucovorin as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a ... | https://www.clinpgx.org/clinicalAnnotation/1043880841 |
1043880841 | rs1979277 | rs1979277 | SHMT1 | AG | 3 | Efficacy | bevacizumab;fluorouracil;irinotecan;leucovorin | Colorectal Neoplasms | Patients with the AG genotype and Colorectal Neoplasms may have 1) increased response, 2) increased progression-free survival and overall survival when treated with bevacizumab, fluorouracil, irinotecan and leucovorin as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a ... | https://www.clinpgx.org/clinicalAnnotation/1043880841 |
1043880841 | rs1979277 | rs1979277 | SHMT1 | GG | 3 | Efficacy | bevacizumab;fluorouracil;irinotecan;leucovorin | Colorectal Neoplasms | Patients with the GG genotype and Colorectal Neoplasms may have 1) decreased response, 2) decreased progression-free survival and overall survival when treated with bevacizumab, fluorouracil, irinotecan and leucovorin as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influe... | https://www.clinpgx.org/clinicalAnnotation/1043880841 |
1043880851 | rs4553808 | rs4553808 | CTLA4 | AA | 3 | Toxicity | bortezomib;dexamethasone;melphalan;prednisone | null | Patients with the AA who are treated with bortezomib, melphalan and prednisone may have a later onset of bortezomib-induced peripheral neuropathy as compared to patients with the GG genotype. However, no association was found for bortezomib and dexamethasone treatment. Other genetic and clinical factors may also influe... | https://www.clinpgx.org/clinicalAnnotation/1043880851 |
1043880851 | rs4553808 | rs4553808 | CTLA4 | AG | 3 | Toxicity | bortezomib;dexamethasone;melphalan;prednisone | null | Patients with the AG who are treated with bortezomib, melphalan and prednisone may have a later onset of bortezomib-induced peripheral neuropathy as compared to patients with the GG genotype. However, no association was found for bortezomib and dexamethasone treatment. Other genetic and clinical factors may also influe... | https://www.clinpgx.org/clinicalAnnotation/1043880851 |
1043880851 | rs4553808 | rs4553808 | CTLA4 | GG | 3 | Toxicity | bortezomib;dexamethasone;melphalan;prednisone | null | Patients with the GG who are treated with bortezomib, melphalan and prednisone may have an earlier onset of bortezomib-induced peripheral neuropathy as compared to patients with the AA or AG genotype. However, no association was found for bortezomib and dexamethasone treatment. Other genetic and clinical factors may al... | https://www.clinpgx.org/clinicalAnnotation/1043880851 |
1043880872 | rs2168631 | rs2168631 | DRD1 | AA | 3 | Efficacy | bupropion;nicotine | null | Patients with the AA genotype may have an increased likelihood of smoking abstinence within slow nicotine metabolizers when exposed to bupropion or nicotine replacement therapy as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to bupropion. | https://www.clinpgx.org/clinicalAnnotation/1043880872 |
1043880872 | rs2168631 | rs2168631 | DRD1 | AG | 3 | Efficacy | bupropion;nicotine | null | Patients with the AG genotype may have an increased likelihood of smoking abstinence within slow nicotine metabolizers when exposed to bupropion or nicotine replacement therapy as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to bupropion. | https://www.clinpgx.org/clinicalAnnotation/1043880872 |
1043880872 | rs2168631 | rs2168631 | DRD1 | GG | 3 | Efficacy | bupropion;nicotine | null | Patients with the GG genotype may have a decreased likelihood of smoking abstinence within slow nicotine metabolizers when exposed to bupropion or nicotine replacement therapy as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to bupropion. | https://www.clinpgx.org/clinicalAnnotation/1043880872 |
1043880900 | rs2306283 | rs2306283 | SLCO1B1 | AA | 3 | Toxicity | HMG-CoA reductase inhibitors | Coronary Artery Disease;Diabetes Mellitus;Hypercholesterolemia | Patients with the AA genotype who are treated with statins (hmg coa reductase inhibitors) may have increased creatine kinase levels, and increased risk of adverse events in response to treatment as compared to patients with the GG or AG genotype, although this is contradicted in some studies. Other genetic and clinical... | https://www.clinpgx.org/clinicalAnnotation/1043880900 |
1043880900 | rs2306283 | rs2306283 | SLCO1B1 | AG | 3 | Toxicity | HMG-CoA reductase inhibitors | Coronary Artery Disease;Diabetes Mellitus;Hypercholesterolemia | Patients with the AG genotype who are treated with statins (hmg coa reductase inhibitors) may have increased creatine kinase levels, and an increased risk of adverse events in response to treatment as compared to patients with the GG genotype, but a lower creatine kinase levels and lower risk of intolerance as compared... | https://www.clinpgx.org/clinicalAnnotation/1043880900 |
1043880900 | rs2306283 | rs2306283 | SLCO1B1 | GG | 3 | Toxicity | HMG-CoA reductase inhibitors | Coronary Artery Disease;Diabetes Mellitus;Hypercholesterolemia | Patients with the GG genotype who are treated with statins (hmg coa reductase inhibitors) may have decreased creatine kinase levels, and may have a lower risk of adverse events in response to treatment as compared to patients with the AA or AG genotype, although this is contradicted in some studies. Other genetic and c... | https://www.clinpgx.org/clinicalAnnotation/1043880900 |
1048764135 | rs16944 | rs16944 | IL1B | AA | 3 | Efficacy | pravastatin | null | Patients with the AA genotype who are treated with pravastatin may 1) have increased IL1B serum levels, and 2) be less likely to benefit from pravastatin treatment in terms of improvement in coronary function, as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient'... | https://www.clinpgx.org/clinicalAnnotation/1048764135 |
1048764135 | rs16944 | rs16944 | IL1B | AG | 3 | Efficacy | pravastatin | null | Patients with the AG genotype who are treated with pravastatin may 1) have increased IL1B serum levels, and 2) be less likely to benefit from pravastatin treatment in terms of improvement in coronary function, as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient'... | https://www.clinpgx.org/clinicalAnnotation/1048764135 |
1048764135 | rs16944 | rs16944 | IL1B | GG | 3 | Efficacy | pravastatin | null | Patients with the GG genotype who are treated with pravastatin may 1) have lower IL1B serum levels, and 2) be more likely to benefit from pravastatin treatment in terms of improvement in coronary function, as compared to patients with the AG or AA genotype. Other genetic and clinical factors may also influence a patien... | https://www.clinpgx.org/clinicalAnnotation/1048764135 |
1050579065 | rs1800591 | rs1800591 | MTTP | GG | 3 | Efficacy | pravastatin | Coronary Artery Disease | Patients with the GG genotype who are treated with pravastatin may be less likely to benefit from treatment as compared to patients with the GT or TT genotype. Other genetic and clinical factors may also influence a patient's response to pravastatin treatment. | https://www.clinpgx.org/clinicalAnnotation/1050579065 |
1050579065 | rs1800591 | rs1800591 | MTTP | GT | 3 | Efficacy | pravastatin | Coronary Artery Disease | Patients with the GT genotype who are treated with pravastatin may be more likely to benefit from treatment as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to pravastatin treatment. | https://www.clinpgx.org/clinicalAnnotation/1050579065 |
1050579065 | rs1800591 | rs1800591 | MTTP | TT | 3 | Efficacy | pravastatin | Coronary Artery Disease | Patients with the TT genotype who are treated with pravastatin may be more likely to benefit from treatment as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to pravastatin treatment. | https://www.clinpgx.org/clinicalAnnotation/1050579065 |
1051394394 | rs1800591 | rs1800591 | MTTP | GG | 3 | Efficacy | atorvastatin | Hyperlipoproteinemia Type II | Men with the GG genotype and Hyperlipoproteinemia Type II who are treated with atorvastatin may have lower decreases in triglyceride levels as compared to patients with the TT genotype. No association with atorvastatin response was seen in women. Other genetic and clinical factors may also influence a patient's respons... | https://www.clinpgx.org/clinicalAnnotation/1051394394 |
1051394394 | rs1800591 | rs1800591 | MTTP | GT | 3 | Efficacy | atorvastatin | Hyperlipoproteinemia Type II | Men with the GT genotype and Hyperlipoproteinemia Type II who are treated with atorvastatin may have lower decreases in triglyceride levels as compared to patients with the TT genotype. No association with atorvastatin response was seen in women. Other genetic and clinical factors may also influence a patient's respons... | https://www.clinpgx.org/clinicalAnnotation/1051394394 |
1051394394 | rs1800591 | rs1800591 | MTTP | TT | 3 | Efficacy | atorvastatin | Hyperlipoproteinemia Type II | Men with the TT genotype and Hyperlipoproteinemia Type II who are treated with atorvastatin may have higher decreases in triglyceride levels as compared to patients with the GT or GG genotype. No association with atorvastatin response was seen in women. Other genetic and clinical factors may also influence a patient's ... | https://www.clinpgx.org/clinicalAnnotation/1051394394 |
1123915607 | rs11749035 | rs11749035 | DRD1 | CC | 3 | Efficacy | bupropion;nicotine | null | Patients with the CC genotype may have a decreased likelihood of smoking abstinence within slow nicotine metabolizers when exposed to bupropion or nicotine replacement therapy as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to bupropion. | https://www.clinpgx.org/clinicalAnnotation/1123915607 |
1123915607 | rs11749035 | rs11749035 | DRD1 | CT | 3 | Efficacy | bupropion;nicotine | null | Patients with the CT genotype may have an increased likelihood of smoking abstinence within slow nicotine metabolizers when exposed to bupropion or nicotine replacement therapy as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to bupropion. | https://www.clinpgx.org/clinicalAnnotation/1123915607 |
1123915607 | rs11749035 | rs11749035 | DRD1 | TT | 3 | Efficacy | bupropion;nicotine | null | Patients with the TT genotype may have an increased likelihood of smoking abstinence within slow nicotine metabolizers when exposed to bupropion or nicotine replacement therapy as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to bupropion. | https://www.clinpgx.org/clinicalAnnotation/1123915607 |
1124035501 | rs11746641 | rs11746641 | DRD1 | GG | 3 | Efficacy | bupropion;nicotine | null | Patients with the GG genotype may have an increased likelihood of smoking abstinence within slow nicotine metabolizers when exposed to bupropion or nicotine replacement therapy as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to bupropion. | https://www.clinpgx.org/clinicalAnnotation/1124035501 |
1124035501 | rs11746641 | rs11746641 | DRD1 | GT | 3 | Efficacy | bupropion;nicotine | null | Patients with the GT genotype may have an increased likelihood of smoking abstinence within slow nicotine metabolizers when exposed to bupropion or nicotine replacement therapy as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to bupropion. | https://www.clinpgx.org/clinicalAnnotation/1124035501 |
1124035501 | rs11746641 | rs11746641 | DRD1 | TT | 3 | Efficacy | bupropion;nicotine | null | Patients with the TT genotype may have a decreased likelihood of smoking abstinence within slow nicotine metabolizers when exposed to bupropion or nicotine replacement therapy as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to bupropion. | https://www.clinpgx.org/clinicalAnnotation/1124035501 |
1127092670 | rs2500535 | rs2500535 | UST | AA | 3 | Efficacy | nortriptyline | Major Depressive Disorder | Patients with the AA genotype and major depressive disorder who are treated with nortriptyline may have decreased improvement of depression symptoms as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to nortriptyline. | https://www.clinpgx.org/clinicalAnnotation/1127092670 |
1127092670 | rs2500535 | rs2500535 | UST | AG | 3 | Efficacy | nortriptyline | Major Depressive Disorder | Patients with the AG genotype and major depressive disorder who are treated with nortriptyline may have decreased improvement of depression symptoms as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to nortriptyline. | https://www.clinpgx.org/clinicalAnnotation/1127092670 |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.